Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab vs trastuzumab + pertuzumab as neoadjuvant therapy in HER2-positive early or locally advanced breast cancer (real-world)
ChiCTR2200056467Phase 2Recruiting
- Sponsor
- Army Medical University
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pyrotinib, trastuzumab and pertuzumab in breast cancer (2 cohorts), sponsored by Army Medical University. Primary endpoint: pCR (pathologic complete response). Started Feb 2022; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200056467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056467.